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Abstract
Introduction: It is accepted that preventing hyperglycaemia during critical illness while assuring adequate caloric intake can reduce mortality 
and morbidity. The aim of this study was to compare the metabolic effects of metformin and insulin on hyperglycaemia in ICU patients.
Methods: This double-blind randomised clinical trial was performed on 24 patients who were admitted to the intensive care unit (ICU) 
from 20 March to 20 September 2007. All patients with serious injuries or with major non-abdominal surgeries were included if they met 
the inclusion criteria, and were assigned randomly to one of the study groups. Patients in Group 1 received intensive insulin therapy, and 
patients in Group 2 were treated with metformin. Moreover, the Acute Physiology And Chronic Health Evaluation (APACHE) II scoring 
system was used to grade disease severity.
Results: Both glycaemic management protocols led to significantly improved glucose levels without any report of hypoglycaemia. The 
mean initial glucose levels for the insulin group decreased significantly after the intravenous infusion of insulin (p < 0.001). Additionally, 
the blood glucose concentration was significantly lower after two weeks of metformin administration compared to baseline measurements 
(p < 0.001). Moreover, the blood glucose concentration decrease during these two weeks was significantly higher in the insulin group 
(p = 0.01). Besides, APACHE II score was lower than baseline at the end of the study for both therapeutic groups (score of 10 vs. 15 [insulin] 
and 16 [metformin]). Finally, new renal dysfunction (maximum serum creatinine level at least double the initial value) was observed in 
three of the patients (two patients from the metformin group and one from the insulin group) in the last days of the protocol, although 
none of the patients showed lactic acidosis after ICU admission.
Conclusions: Both metformin and intensive insulin therapy significantly decreased hyperglycaemia in ICU patients. Insulin caused 
a greater reduction in blood glucose concentration but required more attention and trained personnel. (Pol J Endocrinol 2012; 63 (3): 206–211)
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Streszczenie
Wstęp: Dowody naukowe wskazują, że zapobieganie hiperglikemii u osób w stanie krytycznym przy zapewnieniu odpowiedniego po-
boru kalorii może zmniejszyć śmiertelność i chorobowość. Celem niniejszego badania było porównanie wpływu metforminy i insuliny 
na występowanie hiperglikemii u pacjentów leczonych na oddziale intensywnej opieki medycznej (OIOM).
Materiał i metody: Badanie z randomizacją przeprowadzone metodą podwójnie ślepej próby obejmowało 24 chorych przyjętych na 
OIOM w okresie od 20 marca do 20 października 2007 roku. Wszystkich pacjentów z ciężkimi obrażeniami lub po poważnych zabiegach 
chirurgicznych niedotyczących jamy brzusznej, którzy spełniali kryteria włączenia, przydzielono losowo do jednej z grup terapeutycznych. 
U chorych przydzielonych do grupy 1. stosowano intensywną insulinoterapię, natomiast chorym z grupy 2. podawano metforminę. 
Do oceny ciężkości stanu chorych wykorzystano skalę APACHE (Acute Physiologic Assessment and Chronic Health Evaluation) II.
Wyniki: Oba protokoły leczenia hipoglikemizującego spowodowały istotną poprawę wyrównania glikemii, przy czym nie odnotowa-
no żadnego przypadku hipoglikemii. W grupie stosującej insulinoterapię średnie stężenie glukozy obniżyło się istotnie w stosunku 
do wartości wyjściowych po dożylnym wlewie insuliny (p < 0, 001). U osób leczonych metforminą po 2 tygodniach przyjmowania 
leku stężenie glukozy we krwi było istotnie niższe od poziomu wyjściowego (p < 0,001). Redukcja stężenia glukozy w ciągu tych 
2 tygodni była istotnie większa w grupie przyjmującej insulinę (p = 0,01). W obu grupach terapeutycznych punktacja w skali APACHE II 
w momencie zakończenia badania była niższa od wartości wyjściowych (10 punktów v. 15 [insulina] i 16 [metformina]). U 3 chorych 
(2 osoby przydzielone do leczenia metforminą i 1 osoba przydzielona do insulinoterapii) zaobserwowano rozwój niewydolności 
nerek de novo (maksymalne stężenie kreatyniny w surowicy co najmniej 2-krotnie większe od wartości wyjściowych) w ostatnich 
dniach stosowania protokołu leczenia hipoglikemizującego, chociaż u żadnego z pacjentów nie stwierdzono kwasicy mleczanowej 
po przyjęciu na OIOM.
Wnioski: Zarówno leczenie metforminą, jak i intensywna insulinoterapia istotne zmniejszają hiperglikemię u pacjentów na OIOM. Insulina 
powoduje większą redukcję stężenia glukozy, jednak jej stosowanie wymaga większej uwagi, a personel medyczny musi być odpowiednio 
przeszkolony. (Endokrynol Pol 2012; 63 (3):  206–211)
Słowa kluczowe: hiperglikemia, OIOM, insulina, metformina
207
Endokrynologia Polska/Polish Journal of Endocrinology 2012; 63 (3)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Introduction
Critical illness is defined as any condition in which the 
patient needs mechanical aid or pharmacological agents 
to support failing vital organ functions. Because of the 
emergence of intensive care medicine in recent decades, 
patients now can survive diseases and trauma that were 
previously lethal [1]. Critical illness is associated with 
many endocrine and metabolic disturbances, among 
which are changes to the carbohydrate metabolism. 
Because of the stress of trauma or illness, critically ill 
patients (CIPs) frequently present hyperglycaemia, ir-
respective of whether or not they were diabetic before 
admission [2]. Hyperglycaemia has been detected in 
approximately 50% of non-diabetic intensive care unit 
(ICU) patients with sepsis [3].
It has been suggested that hyperglycaemia during in-
jury compensates for volume loss by promoting the move-
ment of cellular fluid into the intravascular compartment 
or by liberating water bound to glycogen. Alternatively, 
stress hyperglycaemia may have evolved as a means of 
ensuring an adequate concentration of glucose in the blood 
to provide the energy requirements of glucose consu mers 
such as the brain, phagocytes and reparative cells [3].
The causes of stress hyperglycaemia include the 
presence of excessive counter-regulatory hormones 
(glucagon, growth hormone, catecholamine, and glu-
cocorticoid, either endogenous or exogenous), and high 
circulating or tissue levels of cytokines (in particular 
tumour necrosis factor-alpha [TNF alpha] and inter-
leukin-1). These metabolic changes result in the failure 
of insulin to suppress hepatic gluconeogenesis despite 
hyperglycaemia; in addition, insulin-mediated glucose 
uptake into skeletal muscle is impaired [4]. Mechanisms 
include insulin resistance, absolute or relative insulin 
deficiency, impaired glucose metabolism, and the effect 
of medications such as corticosteroids and densely calor-
ic entrance and parenteral nutritional supplements [5].
Several recent studies have shown that the develop-
ment of hyperglycaemia is an important risk factor in 
terms of mortality and morbidity of critically ill patients, 
and also of the mortality and length of ICU and hospital 
stay of trauma patients. Hyperglycaemia is associated 
with infectious morbidity. Similarly in severely burned 
children, the mortality, incidence of bacteraemia and 
fungaemia, and the number of skin grafting procedures 
is higher in hyperglycaemic patients than in normogly-
caemic patients [5].
Insulin remains the obvious treatment for hyper-
glycaemia, although evidence documenting the clinical 
benefit of aggressive insulin therapy in the ICU is scarce 
[4]. Strict control of blood glucose levels, especially 
maintaining it between 80 and 110 mg/dL with insu-
lin, has reduced morbidity and mortality compared to 
tolerating stress hyperglycaemia as a potentially bene-
ficial response. Several clinical complications, such as 
severe infections, acute renal failure and critical illness 
polyneuropathy have been shown to be reduced. In 
addition, the number of patients who developed liver 
dysfunction with hyperbilirubinaemia was lowered 
and the patients needed fewer red blood cell transfu-
sions. Patients were also less dependent on prolonged 
mechanical ventilation and intensive care.
These results support the adoption of this low-cost 
intervention as standard care for critically ill patients 
[1, 6]. Both blood glucose control and the glucose-inde-
pendent effects of insulin appear to contribute to the 
useful effects of this therapy [7].
Although several insulin protocols have been ap-
plied in different settings of CIPs [6, 8, 9], they have 
carried the highest risk of hypoglycaemia [10]. Intensive 
insulin therapy increases entry of potassium and mag-
nesium from the extra-cellular to the intracellular space, 
leading to hypokalaemia and hypomagnesaemia [11, 12] 
which promote insulin resistance [13–15] and a higher 
blood glucose level (BGL). Thus, the administration of 
more insulin is unavoidable, thereby beginning a vicious 
cycle with adverse outcomes. In this regard, blood levels 
of potassium and magnesium as well as BGL must be 
closely monitored during insulin therapy [16].
Metformin has recently been suggested as an alter-
native means of correcting hyperglycaemia in severely 
injured patients [17]. By its inhibition of gluconeogene-
sis and augmentation of peripheral insulin sensitivity, 
metformin directly counters the two metabolic processes 
which underlie injury-induced hyperglycaemia. Metfor-
min has also been shown to increase the rate of muscle 
protein synthesis in patients following severe burn injury 
(unpublished data) and to reduce circulating lipids with-
out affecting insulin secretion [17]. Thus, in a way analo-
gous to that of insulin, metformin may have efficacy in 
critically injured patients as both an anti-hyperglycaemic 
and muscle protein anabolic agent [18]. Although it has 
been suspected for lactic acidosis (LA) [19], several stud-
ies have demonstrated that metformin, per se, does not 
promote LA, and this phenomenon is coincidental with 
other underlying CIs [20, 21].
Except for two trials in small populations of burned 
patients [18, 22], the efficacy of metformin in glycaemic 
control in CIPs and trauma patients has not been stud-
ied. Therefore, Mojtahedzadeh et al. conducted a study 
in which they showed that metformin is a safe adjunct 
that decreases insulin requirements, and they suggested 
the addition of metformin to critically ill patients who 
have difficult titrations of blood glucose levels [23].
Moreover, one of those studies on burned patients 
suggested a potential clinical efficacy of metformin in 
reducing stress-induced hyperglycaemia by increasing 
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glucose clearance [22]. Another study demonstrated a sig-
nificant anabolic effect on muscle protein with metformin 
and a modest response with insulin. Findings also sug-
gest that metformin and insulin may work synergistically 
to further improve muscle protein kinetics [18].
The purpose of this study was to compare the 
metabolic effects of metformin and insulin on hyper-
glycaemia in ICU patients during the height of their 
hyper-metabolic response.
Methods
Patients and study protocol
This double-blind randomised clinical trial was per-
formed on patients who were admitted to the intensive 
care unit (ICU) at Sina hospital in Teheran, Iran from 
20 March to 20 September 2007. All patients with seri-
ous injuries and major non-abdominal surgeries were 
included if they were non-diabetic, had BGL more than 
110 mg/dL, and were diagnosed as having Systemic 
Inflammatory Response Syndrome (SIRS) (Table I). 
Exclusion criteria were any of the following: age more 
than 75 years or less than 18 years, history of diabetes, 
abdominal injuries or surgeries, oral intolerance, severe 
diarrhoea or vomiting, Non Per Os (NPO), blood pres-
sure less than 70 mm Hg, serum bicarbonate less than 
13 mEq/L, blood lactate more than 4.5 mmol/L, serum 
creatinine (cr) level more than 1.2 mg/L, or raised liver 
enzymes.
Each patient was included only once in the study, 
even if he or she had been hospitalised more than once. 
A sample size of 28 was calculated for this study. These 
patients were divided into two groups using a simple 
block randomisation method in blocks of four.
Cannulation of the radial artery was done for all 
patients to facilitate blood sampling and to prevent fre-
quent needle injuries. During ICU admission, patients in 
Group 1 received intensive insulin therapy, and patients 
in Group 2 were treated with metformin.
Before the start of the study, patients were fully 
informed of the format and consequences of the study 
and signed a consent form. This study was conducted 
following approval by the Ethics Committee of Teheran 
University of Medical Sciences and was in accordance 
with the ethical principles described in the Declaration 
of Helsinki.
Glycaemic management protocol  
and glucose measurements
In Group 1, regular insulin that was prepared with 
10 units in 50 ccs 0.9% NaCl was injected in one periph-
eral vein using a syringe pump (SP-500, JMS, Japan). 
The dose of this insulin was determined based on the 
patient’s initial blood glucose according to the data in 
Table II. With regard to the potential risk of hypoglycae-
mia, the patients’ blood glucose was monitored every 
two hours by means of a bedside glucometer (Sapphire, 
Medi Smart, Switzerland). While being in the range 
of 80–110 mg/dL, intravenous injection of insulin was 
ceased for one hour and measurement was repeated 
after one hour and a decision was made according to 
the result. Moreover, in patients who needed more than 
5 units/h insulin, blood glucose was monitored every 
one hour. To equalise the conditions in the two groups, 
blood glucose was also measured every six hours in 
the laboratory.
Patients in Group 2 received oral metformin, with 
a 1,000 mg dosage given at 12-hourly intervals via a na-
sogastric tube, or orally if possible. Their blood glucose 
was assessed in the laboratory every six hours. In this 
group, plasma lactate concentrations were determined 
before the administration of the next dose of metformin 
every 12 hours because of the potential risk of lactatae-
mia, using ACCUT LACTATE machinery (Roche Co). 
If the plasma lactate level exceeded 4.5 mmol/L, or 
increased by more than 2 mmol compared to the pre-
vious measurement, metformin administration would 
be stopped, and the patient excluded from the study.
Table I. Inclusion criteria
Tabela I. Kryteria włączenia do badania
Non-abdominal injuries or surgeries
Blood glucose level more than 110 mg/dL
Diagnosis of Systemic Inflammatory Response Syndrome (SIRS)
Defined as presence of two or more of the following:
— body temperature more than 38°C or less than 36°C
— heart rate more than 90/min
— respiratory rate more than 20/min or Paco2 < 32 mm Hg
— WBC more than 12,000 or less than 4,000 or more than 10% 
Band cell
Table II. Insulin treatment protocol
Tabela II. Protokół insulinoterapii
Blood glucose Insulin [unit/h]
80–110 0
111–130 1
131–150 2
151–170 3
171–190 4
191–210 5
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Health evaluation
The Acute Physiology And Chronic Health Evaluation 
(APACHE) II scoring system [24] was used to grade 
disease severity. To calculate this score, arterial blood 
gas (ABG), electrolytes, complete blood count, and 
Glasgow Coma Score (GCS) level were assessed daily, 
and pulse rate, respiratory rate, blood pressure and 
body temperature was determined every two hours, 
for all patients in both groups.
Statistical analysis
In order to compare the mean values of quantitative 
variables, an independent T-test was performed. Stu-
dent’s paired T-test was used for comparison between 
pre- and post-treatment period measurements in each 
group. Results were expressed as mean ± SD and 
a p value < 0.05 was accepted as significant.
Results
Comparison between metformin group  
and insulin group
A total of 28 patients were included in our study, of 
whom 14 were assigned to each of two therapeutic 
groups. Two patients from the metformin group en-
countered severe conditions and became NPO and 
were excluded from the study. One of the insulin 
group patients died, and another one from this group 
chose not to undergo the study because his wounds 
had healed and he was ready for discharge. Data 
from these patients is not included in this report. Se-
lected characteristics of patients in the insulin group 
and the metformin group who completed the entire 
two weeks of the study are set out in Table III. There 
were no significant differences between insulin and 
metformin-treated patients regarding the number 
of patients, age (p = 0.62), or sex (p = 1). The hos-
pital course of the 24 remaining study subjects was 
uneventful during the two weeks of study, with the 
maintenance of good haemodynamics, urine output, 
and organ function.
Effect of the protocol on glycaemic control
The glycaemic management protocol led to significantly 
improved glucose levels (p < 0.001) without any report 
of hypoglycaemia (defined as glucose values lower than 
40 mg/dL) during the treatment period. The mean (SD) 
and median initial glucose levels for the insulin group 
were 209 (35) mg/dL and 202 mg/dL, respectively. These 
decreased significantly to 125 (7) mg/dL and 126 mg/dL 
after the intravenous infusion of insulin (p < 0.001). 
Measurements of glucose kinetics are shown in Table IV.
The blood glucose concentration was significantly 
(p < 0.001) lower after two weeks of metformin admi-
nistration (the mean (SD) and median of 129 (8) mg/dL 
and 130 mg/dL) compared to the baseline (the mean 
(SD) and median of 177 (22) mg/dL and 182 mg/dL) 
measurements. Moreover, the blood glucose concentra-
tion decrease during these two weeks was significantly 
higher in the insulin group (p = 0.01).
The distribution of glucose values for the insulin 
group and the metformin group is shown in Figure 1.
General condition and organ system dysfunction
The APACHE II score was lower than baseline at the end 
of the study for both therapeutic groups (i.e. scores of 
15 [insulin] and 16 [metformin] vs. 10). New renal dys-
function after ICU admission, defined as initial serum 
creatinine level of 1.5 mg/dL or lower with maximum 
serum creatinine level of 2.5 mg/dL or higher during 
ICU admission or initial serum creatinine level lower 
than 1.5 mg/dL with maximum serum creatinine level 
during ICU admission at least double the initial value 
[6], was observed in three of the patients according to 
the second part of the definition. Two patients from the 
metformin group and one from the insulin group with 
initial creatinine levels of 0.5, 1, and 0.7 achieved levels 
of 1.2, 1, and 1.9 on days 11, 14, and 14 of the treatment 
period, respectively. However, they weren’t excluded 
because their creatinine level was lower than 1.2 mg/dL 
or they had finished the treatment period. Additionally, 
none of the patients showed lactic acidosis, and GCS 
levels were improved significantly in both groups. Mean 
Table IV. Comparison of initial and final glucose values
Tabela IV. Porównanie początkowych i ostatnich wyników 
pomiarów stężenia glukozy
Insulin  
group
Metformin  
group
Initial blood glucose, mean (SD) 209 (35) 177 (22)
Blood glucose after 2 weeks,  
mean (SD)
125 (7) 129 (8)
Blood glucose decrease after  
2 weeks of treatment, mean (SD)
84 (37) 47 (23)
Table III. Baseline patient characteristics
Tabela III. Wyjściowa charakterystyka chorych
Insulin  
group
Metformin  
group
Age (years), mean ± SD 43.16 ± 11.67 39.91 ± 19.05
Gender (M/F) 8/4 9/3
APACHE II score  
(first day/last day)
15/10 16/10
Values are presented as mean ± SD; APACHE — Acute Physiology And 
Chronic Health Evaluation
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increases were from 10.66 to 11.41 in the insulin group 
[p = 0.012], and from 10.58 to 11.41 in the metformin 
group [p = 0.005]).
Discussion
Glycaemic control by protocols
There have only been a few studies investigating the 
role of metformin in critically ill and trauma patients. As 
expected from previous studies [18, 22, 23], metformin 
did significantly decrease hyperglycaemia in ICU pa-
tients. However, our study not only failed to identify 
any superiority of metformin over insulin, but we also 
found that insulin caused a greater reduction in blood 
glucose concentration. Similar to our results, Gore et al. 
[22] found that plasma glucose concentrations were sig-
nificantly lower in those subjects receiving metformin 
than a placebo. Additionally, in another study by Gore 
et al. [18], the arterial glucose concentration was signifi-
cantly lower after one week of metformin administra-
tion compared to baseline measurements. In contrast to 
our study, the intra-arterial infusion of insulin resulted 
in an insignificant (8%) decrease in the arterial con-
centration of glucose, but during metformin treatment 
insulin administration into the femoral artery decreased 
the arterial glucose concentration by a significant 20%, 
which shows the synergistic effect of these two drugs 
on glycaemic control. Likewise, Mojtahedzadeh et al. 
conducted a study in which they sought to investigate 
the effectiveness and safety of metformin in glycaemic 
control in patients traumatised by critical illness by 
measuring the blood glucose, lactate, and pH values, 
in addition to the patients’ insulin requirements when 
insulin was co-administered with metformin. They 
showed that metformin is a safe adjunct that decreases 
insulin requirement, and they suggested the addition 
of metformin to critically ill patients who have difficult 
titrations of BGLs. Additionally no significant difference 
in the control of glycaemia was observed between three 
protocols consisting of insulin (Group A), metformin 
(Group B) and both (Group C). This finding contra-
dicted our result which showed a significantly higher 
decrease in the insulin group. Comparing initial BGL 
and mean weekly values showed a significant reduction 
in Groups A and B, but the 36% reduction in admis-
sion BGL in Group C was not statistically significant. 
However, adjunct therapy caused less need for insulin 
administration [23].
General condition
The APACHE II score was lower than baseline at the 
end of our research for both therapeutic groups. Like-
wise, work by Krinsley et al. [6] has demonstrated 
a median APACHE II score decrease from 16 to 15 after 
treatment with insulin and oral agents. Research by 
Mojtahedzadeh et al. also showed that the reduction 
in basal APACHE II score in Group B (metformin) was 
significant, although no significant difference was ob-
served in weekly APACHE II score between Groups A, 
B, and C or within the patients.
Safety of metformin in CIPs
In our research, none of the treatment protocols led to 
hypoglycaemia. This result is compatible with previ-
ous work [6] in which the percentage of patients with 
marked hypoglycaemia was 0.35% during the baseline 
period and 0.34% during the treatment period. How-
ever, similar to our study, no complications such as 
hypoglycaemia, hypokalaemia, hypomagnesaemia, or 
lactic acidosis was observed in the Mojtahedzadeh et 
al. study [23].
Moreover, in the abovementioned study [6], met-
formin was shown to cause new renal dysfunction after 
ICU admission in three patients, and this is similar to 
our results.
Efficacy of metformin in acute care medicine
Gore’s study [18] would suggest that even if metformin 
is inadequate alone to sufficiently normalise glucose 
concentrations in critically ill patients, its adjuvant use 
may increase insulin’s actions for both improved glycae-
mic control and as an anabolic agent for muscle. Further-
more, metformin may have a clinical use in maintaining 
proper glycaemic control in those survivors of critical 
illness or injury who cannot be safely discharged from 
intensive care because of their continued need for in-
Figure 1. Temporal trend of blood glucose levels in protocols: 
insulin (●) and metformin (▲) during the period of study
Rycina 1. Zmiany stężenia glukozy w czasie u osób leczonych 
insuliną (●) i metforminą (▲) w okresie badania
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sulin and/or the frequent monitoring of plasma glucose 
that is necessary with intensive insulin therapy.
Conclusions
The findings of Mojtahedzadeh et al. [23] are the first 
evidence that metformin is safe in an ICU setting, and 
that metformin improves insulin sensitivity and require-
ments without causing hypoglycaemia.
Similarly, the findings of this study would suggest 
that intensive treatment with both insulin and met-
formin administration is sufficient to normalise plasma 
glucose concentrations in critically ill patients, although 
insulin works more strongly and decreases glucose 
concentrations by more than metformin does.
Both metformin and intensive insulin therapy 
significantly decreased hyperglycaemia in ICU pa-
tients. However, insulin caused a greater reduction in 
blood glucose concentration.
Limitations
Body mass index as an effective factor in insulin resist-
ance had to be matched in two groups; however, we 
were unable to calculate this item for bedridden ICU 
patients.
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